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Abstract
Though recently they have fallen into some disrepute, genome-wide association studies (GWAS) have been formulated and
applied to understanding essential hypertension. The principal goal here is to use data gathered in a GWAS to gauge the
extent to which SNPs and their interactions with other features can be combined to predict mean arterial blood pressure
(MAP) in 3138 pre-menopausal and naturally post-menopausal white women. More precisely, we quantify the extent to
which data as described permit prediction of MAP beyond what is possible from traditional risk factors such as blood
cholesterol levels and glucose levels. Of course, these traditional risk factors are genetic, though typically not explicitly so. In
all, there were 44 such risk factors/clinical variables measured and 377,790 single nucleotide polymorphisms (SNPs)
genotyped. Data for women we studied are from first visit measurements taken as part of the Atherosclerotic Risk in
Communities (ARIC) study. We begin by assessing non-SNP features in their abilities to predict MAP, employing a novel
regression technique with two stages, first the discovery of main effects and next discovery of their interactions. The long
list of SNPs genotyped is reduced to a manageable list for combining with non-SNP features in prediction. We adapted
Efron’s local false discovery rate to produce this reduced list. Selected non-SNP and SNP features and their interactions are
used to predict MAP using adaptive linear regression. We quantify quality of prediction by an estimated coefficient of
determination (R
2). We compare the accuracy of prediction with and without information from SNPs.
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Introduction
Persistent idiopathic elevated blood pressure (BP), or essential
hypertension (HTN), is quantitatively the major risk factor for
untoward cardiovascular outcomes, with wide-ranging prevalence
of 29% in the U.S. Although pathogenic pathways that lead to
HTN remain poorly understood, much of the risk of HTN is
believed to be genetic. Therefore, genetic investigations may lead
to our improved understanding of traits related to HTN and
ultimately to identifying new molecular targets for drug therapy.
Genome-wide association studies (GWAS) are the most recent
form of such efforts and have been employed to interrogate the
genetic architecture of other complex diseases as well as essential
HTN [1]. The number of susceptibility variants that can be
identified definitively by GWAS is limited although they can be
used to gain insights into disease pathways [2,3,4]. Since for
genetically complex disease its heritability caused by mutation
away from wildtype in any single SNP seems quite small,
contributions of these susceptibility SNPs, if any, to prediction of
complex traits of interest is limited. Indeed, as we show in this
article, at least for mean arterial BP, SNPs do not add much and
sometimes diminish, predictive information available from other
clinical features.
From a clinical point of view, we are interested in how much
new information the genome-wide SNPs provide in prediction of a
BP trait in addition to what is achievable from traditional risk
factors, such as blood cholesterol level and glucose level. To this
end, population-based cohort studies that include rich data on
non-SNP clinical biomarkers, if combined with whole-genome
SNP data, could complement case-control studies such as GWAS
in a clinically relevant fashion. This approach shifts the focus of
studies from finding genes that are causally associated with disease
status (which can be understood as multiple hypothesis testing with
very stringent type I error rate imposed in order to avoid false
positives due to the vast number of hypotheses) toward assessing
predictive power for the unobserved phenotype of interest, which
can be modeled by regression with many predictors.
In this article we quantify the impact on mean arterial blood
pressure (MAP), an obvious quantitative phenotype, of more
common genetic variation above and beyond that of other
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of first-visit Atherosclerosis Risk in Communities (ARIC) women.
ARIC was a prospective study, conducted in four U.S. com-
munities, supported by the U.S. National Heart, Lung and Blood
Institute (NHLBI). What makes the ARIC cohort an ideal study
sample is that there were many measurements gathered in clinic,
not least blood pressure measured according to the ARIC protocol
[5]. We chose MAP for the quantitative phenotype of interest.
MAP is one of the four major blood pressure components; systolic
(SBP) and diastolic blood pressure (DBP), pulse pressure, and
MAP. Each has been shown to be associated with cardiovascular
risk, all the better if used in combination [6]. MAP is the average
pressure in the arterial system and was chosen here rather than
SBP or DBP because it represents a physiological (rather than
traditional) component of blood pressure, corresponding to the
product of cardiac output and peripheral resistance minus central
venous pressure [6]. MAP is highly correlated with SBP and DBP
(squared correlation coefficients r
2 of 0.81 and 0.84 in our study
sample, consistent with what has been described by others [7]).
Although the usefulness of MAP as an independent cardiovascular
risk factor beyond SBP and DBP is debated, we would expect very
similar results if SBP or DBP were used in our analysis. MAP can
be estimated by a convex combination of systolic (SBP) and dia-
stolic blood pressure (DBP): 2/3 DBP+1/3 SBP, a simplification
that we take as our definition. Also, MAP as opposed to hyper-
tensive status can be measured, or at least approximated, non-
invasively without the biases related to clinically diagnosed cases
and controls, allowing for subtle phenotypic variability among
individuals. Potential genetic determinants of brachial SBP and
DBP were evaluated in several prior studies [8,9,10,11], but
separate consideration of MAP has not been investigated fully.
We consider the synergistic impacts of SNPs and other features
with initial hypothesis that variation in MAP can be explained
largely by non-SNP features together with SNPs, and the sy-
nergistic effects of their union. To begin, we assess the ability of
non-SNP features to predict MAP for white female subjects.
Predictive analysis of SNPs on MAP is conducted with a novel
regression technique that has two stages: (a) ‘‘main effects’’ and
‘‘interactions’’ are discovered for non-SNP features by applying
classification and regression trees (CART) combined with the
bootstrap for which the sampling units are individual subjects; this
selection of non-SNP features and their interactions enables
assessment of accuracy in predicting MAP; (b) the enormous list of
SNPs genotyped is pared down to a manageable list for the
purpose of combining with non-SNP features in prediction; to that
end, we adapt the local false discovery rate (locfdr) framework [12],
[13] in order to find main effects of SNPs as they bear upon
prediction; we employ then the selected non-SNP and SNP
features to predict MAP using adaptive linear regression. The
crucial rationale here is that a SNP is unlikely to have a synergistic
effect if it shows no individual predictive power. The predictive
power of SNPs and subsequently their synergistic effects are
quantified by an estimated coefficient of determination (R
2). This
number is compared with R
2 estimated from stage (a) in order to
quantify improvement in prediction due to SNPs. We validate the
entire procedure by 10-fold cross-validation.
As stated, the purpose of the proposed predictive modeling is to
assess whether knowledge of genetic variants can improve the
accuracy of prediction, as measured by R
2 of MAP above and
beyond that obtained with conventional risk factors. Note that this is
a slightly different goal from that of typical association studies in the
sense that the selected SNPs need not meet stringent levels of
significance for multiple hypothesis testing. Rather, this addresses
the question of which variants aremostpredictive of MAP, as highly
associated SNPs are not always good predictors of the phenotype
[14]. Hence, cross-validated discovery of the relationship between
genome-wide SNPs and the phenotype of interest is relevant. For
this, model selection approaches are required to find the set of SNPs
that best predicts the phenotype [15]. Model selection is handled by
incorporating the adaptive regression framework.
Methods
All individuals provided written informed consent, including
consent for genetic studies; this research was approved by The
Office of Human Subjects Research Institutional Review Boards of
Johns Hopkins University, Committee JHM-IRB 2 on December 2,
2010. In addition, the research proposed in the ARIC study
including research done for this ancillary study has been carried out
according to guidelines expressed in the Helsinki Declaration.
Study samples
All research was completed with written informed consent and
the data were analyzed anonymously. All clinical investigation was
conducted according to the principles expressed in the Declaration
of Helsinki.
Among the 8861 individuals, all of whom are self-reported
whites, genotyped among the 15,792 ARIC individuals, we se-
lected 3138 females who were premenopausal or naturally post-
menopausal at the first visit. We concentrate on women rather
than men because the genetics of what drives blood pressure is
different in men than women. We focus on pre-menopausal and
naturally post-menopausal women because we do not want
medical interventions to interfere with the joint relationship of
predictors and outcome. For each individual, we used 377,790
unimputed SNPs on the autosomal chromosomes. As non-SNP
clinical features, we used 44 variables that include morphological
and biomarker measurements. The 44 clinical features were
chosen subjectively because it was thought that they would be most
predictive among available ARIC features. Readers can see what
features were available from ARIC (http://www.cscc.unc.edu/
aric/). The full list and the characteristics of these variables for the
sample of subjects included in our analyses are presented in Table
S1. In particular, age at the first visit took values from 44 to 66,
with mean 54.84. Each feature had missing values for at most 2%
of people. We imputed missing values in these non-SNP features
using CART trained on the known values as responses and the
other features as predictors, following [16].
The mean and standard deviation of observed (and treatment
corrected; often in computations of blood pressure, there is an
adjustment that consists of adding 10 mmHg to SBP and 5 mmHg
to DBP for those on anti-hypertensive medication(s) [15]) SBP in
our sample were 117.6 (120.2) and 17.82 (19.41); for DBP they
were 69.76 (71.06) and 9.688 (10.29). The proportion of indi-
viduals taking anti-hypertensive medication was 26.0%.
Model
We employed an additive model in which the phenotype of
interest (MAP) is a linear function of particular non-SNP features,
their interactions, additive genetic effects of SNPs, and the
interactions among the SNPs and the non-SNP features. The
additive model can be written
y~m1zZuzf(Z)vz
X
i~1,...,m
Liaizg(Z,L)bze ð1Þ
where y is a vector of length n representing MAP; 1 is a vector of n
ones; Z is a data matrix for the main effects of the non-SNP
Features as They Predispose to Complex Disease
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SNP features; Li is a column vector of length n having entries 0, 1,
or 2 representing the number of minor alleles at the i-th SNP; and
g(Z,L) is a data matrix for the interactions among the SNPs and
the non-SNP features, with L=[L1,… ,Lm]. m is the overall mean
of MAP; u is a vector of non-SNP main effects; v is a vector of non-
SNP interaction effects; ai is the main effect of i-th SNP; b is a
vector of interactions among the SNPs and the non-SNP features;
e is a vector of residuals.
It bears mention that this paper is about variable selection and
thus is in the spirit of data mining. Note that model (1) is
conditional on data matrix Z, not to speak of being conditional
also on available SNPs: m is a one-dimensional constant; n, the a’s,
and b are (finite dimensional but typically not one-dimensional)
constants. It is fundamental that analyses given in this paper are all
conditional on values of these parameters and data matrices. The
source of randomness in our paper is relevant to bootstrapping
discussed in the next section. Apart from the error e, it arises from
the joint empirical distribution of Z and L. This approach is in
contrast with the prevailing ‘‘components of variance’’ approach
to understanding genetic data [17], which is conditional on a
model having been selected. Its most important part is inference
on the additive random effects of the genetic component in a
preselected model. Randomness is unconditional with respect to
these effects, such as ‘‘percent variance explained.’’ Whatever
percent this is must be taken to be in this context, but not in our
framework. Issues of conditional versus unconditional bases to
inference are pervasive in the statistical literature, perhaps
especially in the analysis of variance and in regression. In short,
variable selection for predictive modeling and estimation of a
component of variance for a given model are simply not the same
thing.
When model selection is the issue, as it is here, Gaussian
assumptions on relevant criteria and their implications for the
distribution of MSE do not apply. Therefore one way to judge
‘‘significance’’ is from some sort of internal validation of an entire
process. The question is one of validation, not of subjective choice
of predictive features or combinations of them. The remainder of
Methods deals with this issue.
Estimation of non-SNP effects
We used CART to select main effects and interactions among
the 44 non-SNP features. The use of CART as an interaction
selector has been advocated widely [18], although it is also well
known that CART fits have large variability. To cope with
potential instability, we applied the bootstrap. We sampled
individuals with replacement 300 times independently. In other
words, the bootstrap sampling unit is an individual. While it may
be that the 3138 samples include family members, this matter was
not considered in our validation because we have no information.
However, it is far from obvious even if we had family structures
that we would want to use them in our problem of variable
selection. One can argue that randomly selected individuals in the
population ‘‘out there’’ come with family structures. These
structures are represented fairly among the ARIC data. If so,
then taking account of family structures is done automatically by
what we have done in our approach where the goal is selection of
features.
For each bootstrap sample, we fit CART using the default
pruning method. For each of the 300 trees, we chose main effects
along every path from the root to the leaf node by picking a feature
if it was ever the feature on which a split was made. For each path,
we chose two- and three-factor interactions as adjacent nodes, i.e.,
parent-child pairs and grandparent-parent-grandchild triples.
With this approach, for each interaction term the corresponding
main effects are also chosen. Among the chosen main effects and
the interaction terms, we selected those that occurred more than a
certain percentage of the maximum 300 occurrences (we tried 1%,
5%, 10%, and 20%).
Trees have been used previously, albeit in ways different from
theirusehere,inordertofind andquantifyparticularinteractionsof
aminoacidsatvarioussitesofgenomes.See, forexample,[19],[20].
Still, features come in groups that are close to collinear. If a pair
of frequent features does not occur simultaneously in a single
bootstrap run of CART, they may compete due to collinearity (cf.
surrogate splits; see [21], pp. 140–142). In order to find groups of
competing features, we performed hierarchical clustering based on
the co-occurrence matrix D [22] such that
Dij~#ij=(#iz#j{#ij)
where #ij is the total number of simultaneous occurrences of
features i and j, #i and #j are there respective number of
individual occurrences. For each cluster C, we selected a centroid
feature using a minimax criterion
centroid(C)~argmini[C maxj[C Dij
(This centroid feature was chosen from among an already existing
list of features.) Using co-occurrence clustering, we obtained final
non-SNP features about 40% fewer than those obtained before
applying this method.
We applied the LASSO adaptive regression in order to assess the
overall predictive power, possibly eliminating features with low
predictive value. Note that CART is not used to directly fit MAP; it
is the LASSO that is fit using the features selected by boostrapped
CART and the co-occurrence matrix-based clustering. We cross-
validated the entire procedure of CART, the bootstrap, the co-
occurrence method, and the LASSO in order to estimate the
coefficient of determination (R
2), defined as the squared correlation
coefficient between the predicted responses and the actual
responses. In this way, we validate the adaptive algorithm and its
predictive power, but not a single model with fixed predictors.
Estimation of main effects of SNPs
In order to assessthe marginal effect of SNPs, so inaddition to the
predictive contribution of the non-SNP features, we computed the
nominalP-value ofeachSNP forthe model (1)withm=1,b=0 (i.e.,
no gene-gene or gene-environment interactions), and the covariates
set to the non-SNP features chosen by bootstrapped CART and the
co-occurrence clustering. SNPs that have low local false discovery
rates [12], [13], a ‘‘local’’ empirical Bayes version of false discovery
rates [23], were selected as candidate predictors in model (1), with
b=0. More precisely, we applied the step-up procedure for local
false discovery rates [24] in order to bound marginal false discovery
rates (mFDR). We tried the bounds 0.2 and 0.5. We validated the
increase in predictive power due to the inclusion of the SNP features
in the LASSO regression using the same cross-validation sets as
those used for validating non-SNP features.
Estimation of interaction effects among SNPs and non-
SNP features
We explored the full model (1) by repeating the procedure of
Section 2.3, but with the chosen SNPs added to the CART
interaction selector. We validated the increase in predictive power
of this approach using the same cross-validation sets as those used
for validating non-SNP features.
Features as They Predispose to Complex Disease
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Non-SNP features alone can achieve a moderate
predictive power
The adaptive prediction algorithm chose 14 to 30 non-SNP
features (see Table 1), and achieved cross-validated R
2 of 24% to
27% for medication-adjusted [25] MAP and mFDR cutoff 0.2
(Table 2, ‘‘non-SNP’’). For unadjusted MAP its predictive
performance was lower (up to 14.6%, same mFDR cutoff; see
Table 2) and the number of chosen non-SNP features ranged from
21 and 44 (Table S2). These features are typical risk factors for
HTN and their interactions.
BecausepredictionisbetterforadjustedMAPthan forunadjusted
MAP, plausibly a search for features predictive of MAP would yield
Table 1. Non-SNP features (above the horizontal line) and interactions (below the horizontal line) chosen by our adaptive
prediction algorithm.
Code feature cutoff fraction of occurrence
0.01 0.05 0.1 0.2
avg coef
CV
count avg coef
CV
count avg coef
CV
count avg coef
CV
count
ANTA07A Waist girth (cm) 2.97E202 2 2.53E202 4 2.88E202 5 1.63E202 7
APASIU01 Apolipoprotein A1 (mg/L) NA NA 2.53E204 4 2.17E204 1 NA NA
APBSIU01 Apolipoprotein B (mg/L) 3.37E205 3 8.38E205 2 NA NA NA NA
BMI01 Body mass index (kg/m
2) 3.23E202 2 1.69E202 2 2.74E202 1 6.15E202 1
CENTERID.B Field center 23.51E201 5 27.11E201 7 22.35E201 2 NA NA
CENTERID.D Field center 21.95E+00 10 22.18E+00 10 21.74E+00 8 21.31E+00 1
CHOLMD02.1 Meds that secondarily lower
cholesterol
8.14E+00 10 8.45E+00 10 8.20E+00 10 7.54E+00 10
CIGT01.2 Cigarette smoking status (% never) 6.01E201 6 8.89E201 7 4.49E201 4 6.28E201 1
CIGT01.3 Cigarette smoking status (% never) 9.73E201 10 1.26E+00 9 8.92E201 6 8.96E201 2
CIGTYR01 Cigarette years of smoking 26.29E204 9 27.00E204 8 25.54E204 6 NA NA
ETHANL03 Usual ethanol intake (g/week) 5.60E203 6 6.21E203 4 2.28E203 3 NA NA
INSSIU01 Insulin (pmol/L) 7.81E204 2 6.11E204 4 3.49E204 4 NA NA
TCHSIU01 Total cholesterol (mmol/L) 5.84E201 1 5.88E201 2 5.80E201 5 5.31E201 10
TRGSIU01 Total triglycerides (mmol/L) 3.58E201 5 3.82E201 9 3.11E201 9 1.34E201 4
V1AGE01 Age at first visit 1.01E201 9 1.31E201 10 1.24E201 10 1.03E201 3
WSTHPR01 Waist-to-hip ratio 1.73E+00 3 1.94E+00 2 4.54E+00 2 5.61E+00 2
ANTA07A:TCHSIU01 8.10E203 5 7.32E203 4 8.17E203 1 NA NA
BMI01:TCHSIU01 3.13E202 2 2.29E202 1 NA NA NA NA
BMI01:TRGSIU01 1.12E202 1 NA NA NA NA NA NA
CHOLMD021:
ANTA07A
NA NA NA NA NA NA 7.32E203 3
CHOLMD021:ANT
A07A:TCHSIU01
1.05E203 4 NA NA 1.04E203 1 NA NA
ERHA21:ANTA07A 7.04E204 10 8.83E204 10 7.56E204 9 1.09E203 4
ERHA21:APBSIU01 4.69E206 1 1.10E205 1 NA NA NA NA
ERHA21:BMI01 2.38E203 8 2.39E203 10 3.17E203 10 4.24E203 9
ERHA21:BMI01:
V1AGE01
7.31E205 1 NA NA NA NA NA NA
ERHA21:CENTERIDB 23.66E203 2 NA NA NA NA NA NA
ERHA21:CIGT013 NA NA NA NA 1.33E203 1 NA NA
ERHA21:INSSIU01 5.44E205 1 NA NA 4.75E205 1 3.09E205 1
ERHA21:TCHSIU01 5.37E203 4 5.86E203 6 9.13E203 4 NA NA
ERHA21:TRGSIU01 4.71E203 4 2.57E203 3 6.12E203 1 NA NA
ERHA21:V1AGE01 9.25E204 5 1.50E203 1 1.25E204 1 NA NA
ERHA21:WSTHPR01 5.09E202 1 NA NA NA NA NA NA
INSSIU01:CIGT012 3.32E203 2 3.42E203 1 NA NA NA NA
INSSIU01:TCHSIU01 NA NA 9.67E204 1 NA NA NA NA
For each cutoff fraction of occurrence in the bootstrapped CART, average coefficient and the number of times the corresponding feature is selected over the 10-fold
cross validation is presented. Results are shown for medication-adjusted mean arterial blood pressure.
doi:10.1371/journal.pone.0027891.t001
Features as They Predispose to Complex Disease
PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27891more of them if the outcome was adjusted. Thus, plausibly, a search
for features using adjusted MAP is generous approach to finding
them. If a feature is not discovered when MAP is adjusted, it may
have particularly limited predictive value.
Inclusion of genome-wide SNPs as main effects did not
significantly increase predictive power
Main effects of the SNPs that were chosen using the local false
discovery rate machinery did not significantly improve R
2 either for
medication-adjusted MAP or for unadjusted MAP (Table 2,
‘‘main’’). Note that the standard errors given in Table 2 are likely
to be underestimates due to correlation among the cross-validation
sets. For adjusted MAP, the 10-fold cross-validation (same vali-
dation set for each fold as used in the previous subsection) of the
prediction algorithm selected 49, 39, 48, and 49 SNPs in union,
respectively fornon-SNPcutoffs1%,5%,10%,and 20%, with 18of
them common. For unadjusted MAP, the numbers were 48, 40, 48,
and68,amongwhich23SNPswereshared.Between adjustedMAP
and unadjusted MAP, there were 31, 22, 25, and 33 common SNPs
for each of the cutoffs. No SNPs known previously to be, or thought
to be, associated with SBP, DBP, and hypertension were found (see
Table S3 for list of SNPs for adjusted MAP).
Interaction effects due to SNPs may have been
subsumed by the non-SNP features
Starting over the CART interaction selector, with the chosen
SNPs added, also did not significantly improve R
2 (Table 2, ‘‘non-
SNP first’’, ‘‘mFDR=0.2’’, ‘‘inter’’). At first glance, this ‘‘interac-
tion’’ approach that includes gene-gene and gene-environment
interactions seems slightly better than the ‘‘main effects only’’
approach of the previous subsection. In fact, the full procedure
hardly found any SNPs: only two (rs1989858 and rs2316757, both
in chromosome 17) appeared in the union of two 10-fold cross-
validation experiments for adjusted and unadjusted MAP.
Inclusion of more SNPs may diminish the quality of
prediction
We raised the SNP selection cutoff (mFDR) from 0.2 to 0.5, to
allow more SNPs into the adaptive regression. For adjusted MAP,
inclusion of them as main effects resulted in 625, 642, 597, and 697
SNPs in union over the 10-fold cross-validation, respectively for
non-SNP cutoffs 1%, 5%, 10%, and 20%, where 268 of those were
common. (For unadjusted MAP, the numbers were 715, 671, 624,
and 795, among which 331 were SNPs that were common to the 10
folds.) Contrary to one popular view, that use of more markers leads
to improvement of predictiveperformance,we observed that R
2 was
reduced, especially when the chosen SNPs were used as main effects
(Table 2, ‘‘non-SNP first’’, ‘‘mFDR=0.5’’).
SNPs alone achieved low predictive power
For comparison, we examined the predictive power of the
algorithm when SNPs were selected first and then the non-SNP
features were added (See Methods). This ‘‘SNPs first’’ approach
Table 2. Coefficient of determination (R
2) estimated using 10-fold cross validation of our adaptive prediction algorithm.
Method mFDR cutoff BP SNP effects cutoff fraction of occurrence
0.01 0.05 0.1 0.2
Non-SNP first 0.2 adjusted non-SNP 0.270 (0.014) 0.271 (0.014) 0.261 (0.015) 0.244 (0.015)
main 20.007 (0.003) 20.009 (0.004) 20.003 (0.003) 20.005 (0.002)
inter 0.001 (0.002) 20.003 (0.004) 0.004 (0.003) 0.001 (0.002)
unadjusted non-SNP 0.146 (0.011) 0.141 (0.011) 0.143 (0.011) 0.130 (0.012)
main 20.002 (0.002) 0.004 (0.003) 0.002 (0.002) 0.000 (0.003)
inter 20.001 (0.003) 0.004 (0.003) 20.007 (0.003) 20.012 (0.005)
0.5 adjusted non-SNP 0.273 (0.014) 0.270 (0.014) 0.260 (0.015) 0.244 (0.014)
main 0.220 (0.020) 0.230 (0.019) 0.232 (0.015) 0.194 (0.012)
inter 0.248 (0.013) 0.250 (0.013) 0.238 (0.014) 0.227 (0.012)
unadjusted non-SNP 0.170 (0.011) 0.170 (0.011) 0.171 (0.011) 0.151 (0.013)
main 0.128 (0.010) 0.133 (0.011) 0.128 (0.013) 0.110 (0.012)
inter 0.170 (0.011) 0.171 (0.011) 0.172 (0.011) 0.147 (0.014)
SNP first 0.2 adjusted SNP only 0.133 (0.010) 0.132 (0.010) 0.133 (0.010) 0.134 (0.010)
non-SNP main 0.268 (0.013) 0.264 (0.012) 0.264 (0.012) 0.260 (0.013)
non-SNP inter 0.271 (0.014) 0.268 (0.014) 0.261 (0.016) 0.249 (0.014)
Non-SNP first+
candidate SNPs
0.2 adjusted non-SNP 0.270 (0.014) 0.271 (0.014) 0.261 (0.015) 0.244 (0.015)
SNP main 0.263 (0.014) 0.264 (0.014) 0.259 (0.016) 0.241 (0.016)
SNP inter 0.269 (0.014) 0.269 (0.014) 0.261 (0.015) 0.248 (0.015)
‘‘Non-SNP first’’: the non-SNP features were first selected and the main effects of SNPs were chosen at the marginal false discovery rate cutoff of 0.2 and 0.5.
‘‘SNP first’’: the main effects of SNPs were first selected at the marginal false discovery rate cutoff of 0.2 and non-SNP effects were later included.
‘‘candidate SNPs’’: the non-SNP features were first selected and the 26 candidate SNPs were included together with the main effects of SNPs that were chosen at the
marginal false discovery rate cutoff of 0.2.
For the column ‘‘BP’’, ‘‘adjusted’’ is for results for medication-adjusted mean arterial blood pressure, and ‘‘unadjusted’’ for unadjusted blood pressure for each cutoff
fraction of occurrence in the bootstrapped CART.
For each method and mFDR cutoff, the first row presents the baseline R
2; ‘‘main’’ and ‘‘inter’’ refers to the increase or decrease in R
2 from ‘‘non-SNP.’’ Standard errors of
the individual R
2 for each of the ten folds are presented within parentheses.
doi:10.1371/journal.pone.0027891.t002
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2, compared to up to 27% of ‘‘other
features first’’ approach under the same condition, although adding
‘‘other features’’ recovered the predictive power of approximately
26% (Table 2, ‘‘SNP first’’). SNPs on their own seem not to have
as much predictive power as other features. With both features
present, the order which feature comes first does not matter.
Candidate SNPs study
Since our unimputed SNPs did not contain SNPs whose
association with blood pressure traits is believed to be known, we
forced models to include these SNPs and quantified their impact
on predicting MAP. We used 26 SNP that are the union of the top
10 loci for each of SBP, DBP, and hypertension traits found in
Table 4 of [8]. However, this also did not improve predictive
power (Table 2, ‘‘candidate SNP’’). Among the 104 SNPs selected
in union, 9 were from the candidate SNPs (see Table 3).
Discussion
Our results indicate that the inclusion of genome-wide
association in addition to carefully chosen non-SNP clinical
information did not result in a significant increase in the predictive
power for mean arterial blood pressure. In other words, non-SNP
features do as well as those with SNPs added, when the
interactions among the former are exploited using the CART
interaction selector. Furthermore, the more information from non-
SNP features that is used, the less information SNPs add. Rather
surprisingly, information from SNPs may diminish the quality of
prediction. This is contrary to what has been reported from other
genome-wide predictive studies [26] on type 1 diabetes (T1D), but
is understandable given the noise inherent in the genome-wide
data, and that T1D is relatively easy to predict. The little
predictive value of genome-wide SNP data has been reported
broadly [27], [28]. These studies are for predicting disease status,
i.e., classification analysis, using SNPs only, while our study aims
to predict a quantitative phenotype and intentionally included
clinical non-SNP information, much of which is genetic. Our
observations seem to support the conjecture [29]:
‘‘… from a theoretical perspective, it can be argued that also
a large number of genes will unlikely have substantial added
predictive value over traditional risk factors if these variants
predispose the risk factors.
‘‘… Genetic variants may improve disease prediction
beyond traditional risk factors when they are involved in
unknown pathways or intermediate factors. New yet
unknown pathways may be more likely for some diseases
than for others.’’
Table 3. List of candidate SNPs used for the analysis presented in the last set of Table 2.
SNP_rs_ID Chr physical_start Gene Symbol SBP association DBP association HTN association algorithm select?
rs12046278 1 10722163 Y Y
rs13401889 2 190618803 Y
rs7571613 2 190513906 LOC653447 Y
rs13423988 2 68764769
rs17806132 2 190416531 PMS1 Y Y Y
rs305489 3 11986162 YY
rs7640747 3 37571808 ITGA9 Y
rs448378 3 170583592 MDS1 Y Y
rs9815354 3 41887654 ULK4 Y
rs899364 8 11366953 YY
rs2736376 8 11155174 Y
rs7016759 8 49574968 Y
rs1910252 8 49569914 Y
rs11775334 8 10109029 MSRA Y Y
rs1004467 10 104584496 CYP17A1 Y
rs11014166 10 18748803 CACNB2 Y Y Y
rs381815 11 16858843 PLEKHA7 Y
rs11024074 11 16873794 PLEKHA7 Y
rs11612893 12 129290571 Y
rs2681472 12 88533089 ATP2B1 Y Y
rs2681492 12 88537219 ATP2B1 Y Y
rs2384550 12 113837113 Y
rs278126 12 118620099 CIT Y
rs3184504 12 110368990 LNK Y Y Y
rs6495122 15 72912697 Y
rs16982520 20 57192114 Y
In columns 5–7, the entry ‘‘Y’’ indicated that the corresponding SNP’s association with the corresponding BP trait was previously identified. The last column shows
which of these SNPs were selected in our adaptive prediction algorithm.
doi:10.1371/journal.pone.0027891.t003
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PLoS ONE | www.plosone.org 6 November 2011 | Volume 6 | Issue 11 | e27891It appears that blood pressure traits, especially MAP, are phe-
notypes for which traditional risk factors confound the pathways.
This is contrary to T1D, where it is believed that a genetic region
with large effects (MHC) exists. Of course, it should be stressed that
these results are limited to the genotyped SNPs. Perhaps including
other SNPs (some causal, possibly yet to be discovered) maybe more
informative.
That ‘‘SNPs first’’ approach was not as good as ‘‘other features
first’’ may hint at the amount of information shared by the SNPs
and the non-SNP features (within the aforementioned limit).
Admittedly much of the information in non-SNP clinical features
is genetic. That adding the non-SNP features recovered the
predictive power of the ‘‘other features first’’ approach may be an
indication that virtually no new genetic information, or at least
predictive utility, can be obtained from the markers considered in
the study. As a quantitative trait, ,13% of R
2 for ‘‘SNPs first’’
(and ,26% for ‘‘other features first’’) is relatively low compared to
the similar figure of merits as low as 33% for mean cellular
hemoglobin (MCH) for the predictive analysis of heterogeneous
stock mice from eight inbred strains [15]. However, the estimated
heritability of MCH in the mice population, the lowest in the study
of [15], is 55%, whereas the heritability of MAP has been
estimated to be roughly 33% in another population [30].
Obviously, the ARIC population is much more heterogeneous
than nearly all laboratory mouse populations. This distinction may
not have been emphasized sufficiently in the literature. For this
reason, the main effects of SNPs found by the adaptive prediction
analysis may not be very reliable.
We realize that there may be a degree of bias associated with our
results. First, all of the genetic variants were chosen from the ARIC
datasetandsoarelikelytofitthe predictionset,alsochosenfromthe
same dataset, better than they might in independent samples. We
consider this to be of minor concern since our focus is on the added
predictive ability of genome-wide predictors, which turns out to be
insignificant. Second, although our model is unconditionally highly
non-linear in the data because it involves a choosing of features
based on their appearances in a succession of cross-validation trees,
our model is more restrictive in comparison with more general
models such as generalized additive models (GAMs). Such an
approach may reduce biases at the expense of added variability in
the chosen model. Another possibility may be to divide MAP into
intervals (e.g., low, medium, and high) much like the prediction of
diseasestatus discussedearlier. However, a majorpoint ofourpaper
isthatwearetryingtopredictactualMAP,and the medicalbasisfor
such division is of question. Third, for a quantitative trait such as
MAP, an adaptive spline model, which is by design smoother than
CART, could be a more efficient alternative than a tree. The
adaptive spline model could also suggest interactions in the first
stage. We carried out an additional experiment in which CART is
replaced by Multivariate Adaptive Regression Splines (MARS; see
Chapter 10 of [31]) for the medication-adjusted MAP with non-
SNP cutoffs 1% and 5%. For consistency, MARS was used as an
interaction selector and the LASSO was fit in the same fashion as
explained in the Method section. With non-SNP features only, we
had cross-validated R
2 of 18.37% (standard deviation 3.58%) for
cutoff 1%; 18.29% (3.56%) for cutoff 5%. With SNPs (mFDR=0.2)
added as main effects the improvement in R
2 was 20.45% (0.82%);
with interaction, it was 20.38% (s.d. 1.1%). This result is similar to
that of CART in that the contribution of the SNPs in predictive
power was not significant. Note that MARS was only used as an
interaction selector. If it subsumed the LASSO component, then
MARS may have performed better than CART subsuming the
LASSO, but it is unlikely that the overall predictive power be
significantly higher than the best value achieved by the combined
CART and LASSO approach.
We acknowledge that our predictive analysis is limited to the
first-visit characteristics, and is therefore a cross-sectional study.
For a predictive analysis to have a clinical utility, it would be
desirable that the features can capture both averages and
longitudinal changes of blood pressure. However, this entails an
additional challenge. Since our study population is mature already
at the first visit (45–66), we think that our cross-sectional analysis
demonstrates reasonably the role of SNPs and other features in a
clinically meaningful fashion.
Finally, we also acknowledge that the R
2 measure used to
quantify the predictive ability of our algorithm is a population
value. Particular individuals at high risk may not be identified
using our method.
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